摘要
小分子在细胞中选择性降解致病菌的研究对各种疾病包括癌症的治疗药物的发展是一种新的方法。我们和其他人已经开发了一系列的小分子化合物的混合蛋白敲除技术,称为SNIPERs(特异性和非遗传性的IAP依赖蛋白消除);和肽的嵌合分子,称为protacs(蛋白靶向嵌合分子),从而导致目标蛋白通过泛素-蛋白酶体途径选择性降解。这些化合物包括两种通过连接器链接的不同配体;一个是一种泛素连接酶配体,另一个是预计这些细胞中蛋白质交联的靶蛋白配体。从理论上讲,任何胞浆蛋白都可以通过这种技术完成降解的目标。到目前为止,几个针对具体诱导的致癌蛋白的泛素化和蛋白酶体降解各种致癌蛋白的SNIPERs和protacs已被开发,导致细胞死亡,生长停滞,或癌细胞迁移的影响。因此,这种蛋白敲除技术在癌症治疗方面有很大的潜力。
关键词: IAP,PROTAC(蛋白靶向嵌合分子),蛋白酶体,蛋白敲除,SNIPER(特异性和非遗传性的IAP依赖蛋白消除),泛素连接酶。
Current Cancer Drug Targets
Title:Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Volume: 16 Issue: 2
Author(s): Nobumichi Ohoka, Norihito Shibata, Takayuki Hattori and Mikihiko Naito
Affiliation:
关键词: IAP,PROTAC(蛋白靶向嵌合分子),蛋白酶体,蛋白敲除,SNIPER(特异性和非遗传性的IAP依赖蛋白消除),泛素连接酶。
摘要: Selective degradation of pathogenic proteins by small molecules in cells is a novel approach for development of therapeutic agents against various diseases, including cancer. We and others have developed a protein knockdown technology with a series of hybrid small compounds, called SNIPERs (Specific and Nongenetic IAP-dependent Protein ERasers); and peptidic chimeric molecules, called PROTACs (proteolysis-targeting chimeric molecules), which induce selective degradation of target proteins via the ubiquitin-proteasome pathway. These compounds include two different ligands connected by a linker; one is a ligand for a ubiquitin ligase and the other is a ligand for the target protein, which are expected to crosslink these proteins in cells. Theoretically, any cytosolic protein can be targeted for degradation by this technology. To date, several SNIPERs and PROTACs against various oncogenic proteins have been developed, which specifically induce polyubiquitylation and proteasomal degradation of the oncogenic proteins, resulting in cell death, growth arrest, or impaired migration of cancer cells. Thus, this protein knockdown technology has a great potential for cancer therapy.
Export Options
About this article
Cite this article as:
Nobumichi Ohoka, Norihito Shibata, Takayuki Hattori and Mikihiko Naito , Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy, Current Cancer Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1568009616666151112122502
DOI https://dx.doi.org/10.2174/1568009616666151112122502 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Adjunctive Value of Diffusion Weighted Imaging in Diagnosis and Follow Up of Uterovaginal Diffuse B-cell Lymphoma: A Case Report and Literature Review
Current Medical Imaging Cigarette Smoking, Metabolic Activation and Carcinogenesis
Current Drug Metabolism The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary <i>In Silico</i>, <i>In Vitro</i> and <i>In Vivo</i> Investigation
Current Medicinal Chemistry The Effect of Educational Intervention Based on Health Belief Model on Beliefs Towards Human Papillomavirus Vaccination in a Sample of Iranian Female Nursing Students
Current Women`s Health Reviews Hypoxia Responsive Drug Delivery Systems in Tumor Therapy
Current Pharmaceutical Design Natural Products as Leads for Tuberculosis Drug Development
Current Topics in Medicinal Chemistry Cellular and Physiological Effects of Ganoderma lucidum (Reishi)
Mini-Reviews in Medicinal Chemistry Advancement of Traditional Chinese Medicine in Regulation of Intestinal Flora: Mechanism-based Role in Disease Management
Recent Patents on Anti-Cancer Drug Discovery The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Regioselective Synthesis of Biologically Important Scaffold Spiro [Indole- Perimidines]: An Antitumor Agents
Letters in Organic Chemistry Targeted Biological Effect of An Affitoxin Composed of an HPV16E7 Affibody Fused with Granzyme B (Z<sub>HPV16E7</sub>-GrB) Against Cervical Cancer <i>In vitro</i> and <i>In vivo</i>
Current Cancer Drug Targets Control of Neuropathic Pain by Immune Cells and Opioids
CNS & Neurological Disorders - Drug Targets Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry Long Non-Coding RNA GAS5 in Age-Related Diseases
Current Medicinal Chemistry